Umbrella Biomarker-Guided Therapy in NPC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

GP+DDP

Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

DRUG

Palbociclib

Administered orally

RADIATION

Intensity-modulated radiotherapy

Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day

DRUG

PD-1 blocking antibody

Administered every 3 weeks

DRUG

Galunisertib

Administered orally

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER